Combination Immunotherapy Targeting Sarcomas

The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged. Another goal of the study is to assess the safety and efficacy of the therapy that combines multiple CAR T cells followed by sarcoma vaccines.

Trial Details

NCT ID

NCT04433221

Phase

PHASE1 / PHASE2

Sponsor

Shenzhen Geno-Immune Medical Institute

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

Multiple sarcoma-specific CAR-T cells and sarcoma vaccines

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Stage Ⅲ，Ⅳ sarcoma patients or recurrent sarcoma patients;
Age: ≥ 6 months and ≤80 years of age at the time of enrollment;
At least 2 weeks since the last standard chemotherapy or radiotherapy and immunosuppressive therapy such as steroid hormone before enrollment;
Side effects of chemotherapy have been well managed;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →